SREBF1 and metabolic dysfunction-associated steatotic liver disease: The natural product diosgenin downregulates the gene expression of SREBP-1c, FAS, and SCD and upregulates the gene expression of FoxO1, ATGL, and CPT through the SIRT1/AMPK signaling pathway, promoting lipolysis and thus preventing the progression of NAFLD (Table S1) [123].